Skip to main content
Clinical Trials/KCT0008240
KCT0008240
Not yet recruiting
未知

ecessity and effectiveness of empirical antibiotic use in mild to moderate acute inflammatory gallbladder disease; a Multicenter double-blind, randomized, placebo-controlled trial

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
The Catholic University of Korea, Seoul St. Mary's Hospital
Enrollment
370
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • ? Patients who are scheduled to undergo laparoscopic surgery among patients with acute cholecystitis who have no evidence of systemic infection between the ages of 19 and 70
  • ? Patients with acute cholecystitis with preserved gallbladder walls in the group of patients with acute cholecystitis (grade I by Tokyo guidelines) and moderate (grade II)
  • ? Cholecystitis with gallbladder wall thickness of more than 4mm or adhesion to surrounding organs due to gallbladder inflammation
  • ? A person who voluntarily signs a written consent form after hearing and understanding the description of this clinical trial

Exclusion Criteria

  • ? Those who are scheduled to undergo elective gallbladder surgery (chronic cholecystitis, etc.)
  • ? gallbladder disease, not inflammatory disease (GB Cancer, GB polyp)
  • ? Among the patients with acute cholecystitis, patients with grade II or III by Tokyo guidelines with unpreserved gallbladder walls
  • ? Pregnant or lactating women
  • ? A person who performs surgery simultaneously due to other organ diseases.
  • ? Those with immunosuppressive and hemorrhagic tendencies
  • ? A person who performed percutaneous cholecyst drainage (PTGBD) before alcohol
  • ? A person who is required to install a drainage tube during surgery
  • ? People who overreact to cephalosporin antibiotics.
  • ? A person who participates in another clinical trial within 3 months prior to screening

Outcomes

Primary Outcomes

Not specified

Similar Trials